Posting of Annual Report & Notice of AGM

RNS Number : 7290L

ReNeuron Group plc

15 August 2013

 



For Immediate Release

AIM: RENE

ReNeuron Group plc

("ReNeuron" or the "Company")

Posting of Annual Report & Accounts and Notice of AGM

Guildford, UK, 15 August 2013: ReNeuron Group plc (AIM: RENE) announces that its Annual Report and Accounts for the year ended 31 March 2013 and the Notice of the 2013 Annual General Meeting ("AGM") have been sent to shareholders and will be available shortly on the Company's website, www.reneuron.com. 

ReNeuron's AGM will be held at 10.00am on 13 September 2013 at the offices of Covington & Burling LLP, 265 Strand, London, WC2R 1BH.

Enquiries:

ReNeuron                                                                                                                              [phone]

Michael Hunt, Chief Executive Officer

Pat Huggins, Head of Finance

Buchanan                                                                                                                              [phone]

Mark Court, Fiona Henson, Sophie Cowles

Cenkos Securities                                                                                                                 [phone]

Stephen Keys, Adrian Hargrave (NOMAD and Broker)

Andy Roberts (Sales)

About ReNeuron

ReNeuron is a leading, clinical-stage stem cell business.  Its primary objective is the development of novel stem cell therapies targeting areas of significant unmet or poorly met medical need.  

ReNeuron has used its unique stem cell technologies to develop cell-based therapies for significant disease conditions where the cells can be readily administered "off-the-shelf" to any eligible patient without the need for additional immunosuppressive drug treatments.  ReNeuron's lead candidate is its ReN001 stem cell therapy for the treatment of patients left disabled by the effects of a stroke. This therapy is currently in clinical development.  The Company is also developing stem cell therapies for other conditions such as critical limb ischaemia, a serious and common side-effect of diabetes, and blindness-causing diseases of the retina such as retinitis pigmentosa.

ReNeuron has also developed a range of stem cell lines for non-therapeutic applications - its ReNcell® products for use in academic and commercial research.  The Company's ReNcell®CX and ReNcell®VM neural cell lines are marketed worldwide under license by USA-based Merck Millipore.

ReNeuron's shares are traded on the London AIM market under the symbol RENE.L.  Further information on ReNeuron and its products can be found at www.reneuron.com.

 

END

 

 

MSCGGURWRUPWGQC